Education
About Us
Working with TipRanks
Follow Us
co.don AG (DE:CNW)
BERLIN:CNW
CNW Stock Chart & Stats
Day’s Range― - ―
52-Week Range€0.01 - €0.04
Previous CloseN/A
Volume31.25K
Average Volume (3M)1.00
Market Cap
€494.38K
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)6.30M
Price to Earnings (P/E)―
Beta0.29
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding26,723,358
10 Day Avg. Volume5
30 Day Avg. Volume1
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
CNW FAQ
What was co.don AG’s price range in the past 12 months?
co.don AG lowest stock price was €0.01 and its highest was €0.04 in the past 12 months.
What is co.don AG’s market cap?
co.don AG’s market cap is €494.38K.
When is co.don AG’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were co.don AG’s earnings last quarter?
Currently, no data Available
Is co.don AG overvalued?
According to Wall Street analysts co.don AG’s price is currently Overvalued.
Does co.don AG pay dividends?
co.don AG does not currently pay dividends.
What is co.don AG’s EPS estimate?
co.don AG’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does co.don AG have?
co.don AG has 26,723,358 shares outstanding.
What happened to co.don AG’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of co.don AG?
Currently, no hedge funds are holding shares in DE:CNW
co.don AG Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Company Description
co.don AG
Codon AG develops, produces and distributes autologous cell therapies for the minimally invasive repair of cartilage defects. The product being marketed is a cell therapy product for the minimally invasive treatment of cartilage damage in the knee joint that uses only the patient's own cartilage cells (autologous chondrocytes). CODON's method is currently used in over 200 clinics in Germany and more than 14,000 patients have already been treated.
Technical Analysis
4SC AG
―
B.R.A.I.N. Biotechnology Research and Information Network
―
Epigenomics
―
Heidelberg Pharma AG
―
CytoTools AG
―